Sign Up Today and Learn More About Salvia BioElectronics Stock
Invest in or calculate the value of your shares in Salvia BioElectronics or other pre-IPO companies through EquityZen's platform.
Salvia BioElectronics Stock
Salvia BioElectronics develops neuromodulation devices for migraine treatment and management.
About Salvia BioElectronics Stock
Founded
2017
Industries
Internet Services, Payments, Blockchain and Crypto
Salvia BioElectronics Press Mentions
Stay in the know about the latest news on Salvia BioElectronics
Digital Migraine Treatment Devices Market to Reach USD 298.71 Million by 2030, Fueled by Non-Invasive Neuromodulation and Expanding Clinical Adoption | DataM Intelligence
prnewswire • Sep 25, 2025
Digital Migraine Treatment Devices Market to Reach USD 298.71 Million by 2030, Fueled by Non-Invasive Neuromodulation and Expanding Clinical Adoption | DataM Intelligence
prnewswire • Sep 24, 2025
Swiss VC investment in H1 reflects global trends
startupticker • Aug 08, 2025
Funding focus: Biotech dominates Netherlands’ top 10 rounds in H1 2025
thenextweb • Jul 09, 2025
These companies raised the 10 largest funding rounds in the Netherlands in H1 2025; 6 of them are hiring now
siliconcanals • Jul 02, 2025
Salvia BioElectronics Management
Leadership team at Salvia BioElectronics
CMO
Wim Pollet
Board Member
Sascha Alilovic
Join now and verify your accreditation status to gain access to:
- Salvia BioElectronics Current Valuation
- Salvia BioElectronics Stock Price
- Salvia BioElectronics Management
- Available deals in Salvia BioElectronics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Salvia BioElectronics Cap Table and Funding History by Share Class and Liquidity Preferences
- Salvia BioElectronics Revenue and Financials
- Salvia BioElectronics Highlights
- Salvia BioElectronics Business Model
- Salvia BioElectronics Risk Factors
- Salvia BioElectronics Research Report from SACRA Research
Trading Salvia BioElectronics Stock
How to invest in Salvia BioElectronics stock?
Accredited investors can buy pre-IPO stock in companies like Salvia BioElectronics through EquityZen funds. These investments are made available by existing Salvia BioElectronics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Salvia BioElectronics stock?
Shareholders can sell their Salvia BioElectronics stock through EquityZen's private company marketplace. EquityZen's network includes over 410K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 50K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."